Summary The monoclonal antibody (MAb) G250 binds to a tumour-associated antigen, expressed in renal cell carcinoma (RCC), which has been demonstrated to be a suitable target for antibody-mediated immunotherapy. A bispecific antibody having both G250 and anti-CD3 specificity can cross-link G250 antigen-expressing RCC target cells with T cells and can mediate lysis of such targets. Therapy studies with murine antibodies are limited by immune responses to the antibodies injected (HAMA response), which can be decreased by using chimeric antibodies. We generated a chimeric bispecific G250/anti CD3 MAb by transfecting chimeric genes of heavy and light chains for both the G250 MAb and the anti-CD3 MAb into a myeloma cell line. Cytotoxicity assays revealed that the chimeric bispecific MAb was capable of mediating lysis of RCC cell lines by cloned human CD8+T cells or by IL-2-stimulated peripheral blood lymphocytes (PBLs). Lysis mediated by the MAb was specific for target cells that expressed the G250 antigen and was effective at concentrations as low as 0.01 pg ml-'. The chimeric bispecific G250/anti-CD3 MAb produced may be an effective adjuvant to the currently used IL-2-based therapy of advanced renal cell arcinoma.
Targeting cytotoxic effector cells for localisation in tumours has been pursued as an attractive therapeutic option. One approach is the use of bispecific monoclonal antibodies that can cross-link tumour cells with activation-related molecules on effector cells, such as the CD3 complex on cytotoxic T lymphocytes (CTLs) or with Fc receptors on monocytes and natural 'killer (NK) cells (Fanger et al., 1990) . Cross-linking of CD3 by bispecific antibodies can redirect the specificity of activated T lymphocytes and circumvents MHC restriction (Garrido et al., 1990; Berg et al., 1991; Brissinck et al., 1991; Qian et al., 1991; Nistico et al., 1992) . It has been shown that intravenously administered bispecific MOvl8/anti-CD3 (OC/ TR) MAb, recognising both the ovarian carcinomaassociated antigen MOv18 and the CD3 complex, can localise in tumours in patients (Tibben et al., 1993) . Targeted T lymphocytes, bearing bispecific antibody bound to their CD3 complex, may accumulate in the tumour, whereas any bispecific MAb binding to tumour cells first (Van Dijk et al., 1991) , may subsequently attract circulating T cells.
Monoclonal antibody (MAb) G250 recognises an antigen expressed on human renal cell carcinoma (RCC, Oosterwijk et al., 1986) . Whole immunoglobulin molecules and F(ab)2 fragments of the G250 MAb localised preferentially in tumours, both in model studies with RCC xenografted nude mice and RCC patients, and were suitable for tumour visualisation in mice (Van Dijk et al., 1988 and in patients (Oosterwijk et al., 1993) . Therapeutic effects of murine G250 IgG2a were demonstrated by tumour growth inhibition studies in nude mice xenografted with RCC (Van Dijk et al., 1994) . The G250 antigen can therefore be considered a suitable target for antibody-mediated immunotherapy. Murine bispecific G250/anti-CD3 antibody has previously been generated and was shown to induce lysis of RCC cell lines by IL-2-activated human CTLs in vitro (Van Dijk et al., 1989) . In nude mice F(ab)2 fragments of the murine bispecific G250/anti-CD3 MAb localised well in xenografted RCC (Van Dijk et al., 1991) .
To cure established RCC will require intensive treatment with multiple MAb injections over an extended period.
Repeated administration of murine antibodies to patients frequently elicits a human anti-mouse antibody (HAMA) response (Courtnay-Luck et al., 1986; Schroff et al., 1985; Shawler et al., 1985; Saleh et al., 1993; Riva et al., 1993) . Chimeric antibodies, in which the murine constant regions of the heavy and light chain are replaced by those of human origin, are less immunogenic and have a longer serum halflife than murine antibodies (LoBuglio et al., 1989; Meredith et al., 1991) . The strong immunogenicity of murine G250 and anti-CD3 MAbs observed in patients, was absent when the chimeric versions of these antibodies were injected (Oosterwijk et al., 1993; Canevari et al., 1995; E Oosterwijk, personal communication; Coney et al., 1996) . Based on the observation that chimerisation abrogates the immunogenicity of the parental G250 and the anti-CD3 MAb in patients, we expect the chimeric bispecific G250/anti-CD3 MAb to be non-immunogenic. We generated a chimeric version of the bispecific G250/ anti-CD3 antibody to enable treatment of patients with the bispecific G250/anti-CD3 MAb. To this end the nonimmuno-globulin-producing myeloma cell line, P3X-63Ag8.653, was transfected with expression vectors encoding the chimeric heavy and light chains of the anti-CD3 and the G250 antibody. Transfectants that produced bispecific antibody were selected and were used for antibody purification. The chimeric bispecific antibody was found to bind specifically to the G250 antigen expressed on RCC cell lines and to CD3 on human T lymphocytes. In vitro cytotoxicity assays showed that the chimeric bispecific G250/anti-CD3 MAb is capable of inducing lysis of G250-positive RCC cell lines by IL-2-activated human T lymphocytes as well as peripheral blood lymphocytes (PBLs).
Materials and methods

Cell lines
The non-immunoglobulin-producing murine myeloma cell line P3X63Ag8.653 (ATCC CRL 1580) and the T cell line HPB-ALL were cultured in Iscove's modified Dulbecco's medium supplemented with 2 mM L-glutamine and 5% heatinactivated fetal calf serum (FCS) Memorial Institute (NY, USA), were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FCS and penicillin/streptomycin (P/S, GIBCO-BRL Life Technologies, Breda, The Netherlands). Adherent cells were passaged at confluence with 0.5% trypsin and 0.01% EDTA. The human CD3+CD8+T cell clone, TIL 7.9, was derived from tumour-infiltrating lymphocytes of a cervical carcinoma (kindly provided by W van Driel, Leiden, The Netherlands). The TIL7.9 cells were cultured in 96-well round bottom microtitre plates in RPMI-1640 medium containing 10% human AB serum, P/S, 4 mM L-glutamine, 1 jg ml-1 leucoagglutinine, 1 jug ml-' indomethacine, 10 U ml-' IL-2 (Eurocetus, Amsterdam, The Netherlands) in the presence of feeder cells irradiated with 30 Gy. The feeder cell population contained the EBV-transformed human B cell lines, APD and BSM (kindly provided by Dr R Bolhuis, Rotterdam, The Netherlands), pooled human PBLs and the autologous cervical carcinoma cell line, CSCC-7, at concentrations of 20 000 cells per well for PBLs and 5000 cells per well for the B cell lines and tumour cells respectively. The transfectoma cell lines anti-CD3 4B5, producing chimeric anti-CD3 MAb, and chG250 7C1, producing chimeric G250 MAb, were kindly provided by Centocor (Leiden, The Netherlands), and were cultured in RPMI mixed with DMEM in a 1: 1 volume ratio, supplemented with 10% FCS, P/S, 4 mM L-glutamine and 0.02 mM P-mercaptoethanol.
Expression vectors
Expression vectors containing the chimeric heavy and light chain genes for the G250 MAb, pSV2gptHGI-G250 (chimeric heavy chain vector) and pSV2gptHCKG250 (chimeric light chain vector), and the anti-CD3 MAb, pSV2gptHGI-CD3 (heavy chain) and pSV2neoHCKCD3 (light chain), had previously been constructed (Coney et al., 1996) . The chimeric genes were composed of the murine VH and VK regions connected to the human CH and CK regions respectively. The anti-CD3 coding genes had previously been derived from the OC/TR cell line, described by Mezzanzanica et al. (1988) flat bottom 96-well microtitre plates at a density of 10 000, 5000 and 2500 cells per well. Cells were cultured at 37°C and 5% carbon dioxide for 48 h, followed by the addition of G418 (0.5 mg ml-'). G418-resistant transfectants were screened for chimeric antibody production by ELISA after 2 weeks and the transfectant that produced the highest levels of chimeric anti-CD3 MAb was retransfected with 10 ug XhoI-linearised pSV2gptHGl-G250/HCKG250 double plasmid. Transfectants were selected in medium containing 0.25 jg ml-' mycophenolic acid, 1.25 jug ml-' hypoxanthine, 25 jug ml-' xanthine and 0.5 mg ml-1 G418. Figure 1 ). The presence of antibodies with G250 specificity in the culture supernatant of the transfectants was analysed by ELISA using plates coated with anti-idiotype G250 MAb and goat anti-human IgG MAb as detecting antibody as described in Materials and methods. Twenty transfectants that produced antibodies with G250 specificity were selected for analysis of bispecific G250/ anti-CD3 MAb production. The production of chimeric bispecific antibody was analysed by flow cytometry using HPB-ALL T cells, which express the CD3 antigen. HPB-ALL T cells were incubated with culture supernatant of the transfectants followed by the incubation with anti-idiotype G250 MAb (Figure 2a) . Control incubations of HPB-ALL T cells with only antiidiotype G250 MAb revealed that the anti-idiotype G250 MAb did not react with the HPB-ALL cells, and therefore Antibody purification T3 no. 36.4 cells, producing chimeric bispecific G250/anti-CD3 MAb, were cultured in a 1-1.5 1 culture volume and the supernatant was concentrated ten times using a ProVario-3 filter system with a 70 kDa membrane cassette (Filtron Technology, Terheijden, The Netherlands). Chimeric IgGI was purified from the concentrated supernatant on a protein A-Sepharose column using 0.1 M citrate buffer at pH 3.0 for antibody elution. The bispecific antibody fraction was separated from parental antibody by high pressure liquid chromatography (HPLC) on Mono S -Sepharose using a sodium chloride gradient from 0 to 0.2 M in 25 mM sodium acetate, pH 5.0, a matrix and procedure that had previously been described (van Ravenswaay Claasen et al., 1993; Warnaar et al., 1994; van Dijk et al., 1989 human IgG MAb as detecting antibody to determine the total amount of antibodies with anti-CD3 specificity present in the culture supernatant of the transfectants (Figure 2b and   d) . Subsequently, the capacity of culture supernatant of the transfectants producing chimeric bispecific cG250/anti-CD3 MAb to trigger activated human CD8+T cells for lysis of target cells that express the G250 antigen was analysed in a cytotoxicity assay. Figure 3 shows the results of supernatant of transfectant T3 no. 36.4. The chimeric bispecific G250/ anti-CD3 MAb greatly increased the lysis of A704 target byw activated T cells, as was observed for the control murine bispecific G250/OKT-3 (anti-CD3) MAb at effector-target ratios ranging from 50: 1 to 6: 1. (Figure 5 ).
Induction of lysis mediated by peak 2 (cG250/anti-CD3) was still detectable at an antibody concentration of 0.01 ig ml-' (Figure 5 ), which shows that bispecific antibody-mediated cytotoxicity is effective at low doses of antibody. Tumour cell lines that did not express the G250 antigen were not lysed in the presence of the bispecific antibody. The chimeric bispecific MAb mediated lysis of target cells with a relatively low expression of the G250 antigen as well as targets with a higher expression of the G250 antigen ( Figure  6 ). The efficiency of lysis of G250-expressing cells, induced by chimeric bispecific MAb, was dependent on the concentration of the bispecific MAb as well as on the target cell line used.
As low levels of G250 expression on T cells might lead to cytokine release and autokill of T cells by the chimeric bispecific G250/anti-CD3 MAb, we have tested TNF-a release by T cells in the presence of the chimeric bispecific MAb, using the WEHI assay (Luiten et al., 1996) . No TNF-oa release was seen at concentrations of 0.1 jug ml-' bispecific MAb or parental G250 MAb, whereas chimeric anti-CD3 MAb did lead to TNF-a release.
Based on the binding specificities of both antibody peaks and the difference in capacity to induce cytotoxicity by T cells, peak 2 was considered to contain chimeric bispecific G250/anti-CD3 MAb.
Analysis of mRNA expression for antibody heavy and light chains In the chromatogram of the HPLC separation of the chimeric bispecific antibody fractions a third peak, representing the parental anti-CD3 MAb, was absent. This might indicate that one of the chains for the anti-CD3 MAb was not produced by clone T3 no. 36.4, inhibiting the production of parental anti-CD3. Therefore, the presence of anti-CD3 andG250 MAb heavy and light chain mRNA in the chimeric bispecific MAb-producing transfectant, T3 no. 36.4, was determined by RT-PCR using primer sets specific for the variable regions of the G250 or the anti-CD3 MAb heavy and light chains. The parental cell line and cell lines producing either chimeric anti-CD3 MAb or chimeric G250 MAb were used as control cell lines to check the specificity of the primers. Figure 7 shows that the primer sets specific for the variable regions of anti-CD3 MAb heavy and light chains generated a PCR product of mRNA derived from the anti-CD3 MAbproducing cell line as well as of mRNA derived from the chimeric bispecific-producing clone, T3 no. 36.4, indicating that the transfectant contains mRNA for both anti-CD3 antibody chains. In the control experiment these primer sets did not yield a PCR product with the G250 MAb-producing cell line not containing anti-CD3 MAb mRNA. Analogous results were obtained in analyses for the G250 antibody mRNA. From both the G250 MAb-producing cell line and the clone T3 no. 36.4 a PCR product was obtained with primer sets specific for either the heavy or light chain variable regions of G250 MAb, and not from the anti-CD3 MAbproducing cell line. Clone T3 no. 36.4 appeared to contain mRNA for heavy and light chains of both the anti-CD3 and the G250 MAb, indicating that all chains transfected were expressed in clone T3 no. 36.4.
Cytotoxicity of human PBLs mediated by the chimeric bispecific MAb
Bispecific antibody-mediated cytotoxicity in vivo will deal with lymphocytes of various phenotypes as effector cell population. To show that our chimeric bispecific antibody is capable of inducing lysis by a heterogenous population of lymphocytes, peripheral blood lymphocytes (PBLs) of different donors were used as effector cells. Since chimeric bispecific MAb was unable to induce cytotoxicity with unstimulated PBLs or with PBLs after an overnight stimulation with 100 U ml-' IL-2 (van Ravenswaay Claasen et al., 1993), PBLs were cultured with 100 U ml-' IL-2 for 6 days before cytotoxicity assays. Figure 8 shows that the chimeric bispecific G250/anti-CD3 MAb induced significant lysis of A704 targets with PBLs from donor A or donor C compared with controls without antibody, whereas PBLs from donor B showed a marginal enhancement of lysis. Parental chimeric anti-CD3 MAb and G250 MAb do not mediate cytotoxicity of activated PBLs at the concentration of 1 ig ml-' (data not shown). Activation of PBLs from donor A, but not donor B, enhanced the level of lysis of SK-RC-7 target cells mediated by chimeric bispecific G250/anti-CD3 MAb (data not shown). The amount of lytic activity that was induced in a 4 h incubation varied between donors ( van Ravenswaay Claasen et al., 1993) . This might be owing to differences in the percentage of CD8' cells among the IL-2-stimulated PBLs.
Flow cytometric analysis revealed that PBLs from donor A indeed contained more CD8+T cells (45%) than PBLs from donor B (24%). These results show that IL-2-activated PBLs can be triggered to lyse G250 antigen-positive RCC target cells in the presence of bispecific cG250/anti-CD3 MAb.
Discussion
Renal cell carcinoma has been studied intensively to evaluate different approaches to immunotherapy. Phase I and II clinical trials in which patients with RCC were treated with IL-2 revealed the susceptibility of RCC to IL-2, but also snowed the toxicity of this cytokine when administered systemically in high doses. IL-2-based therapy is therefore limited by maximum tolerated dose (Gaynor et al., 1990) . The response rates between these trials varied between 12 and 30% (Marumo et al., 1989; Hayat et al., 1991; Jensen et al., 1990; Whitehead et al., 1990; Rosenberg et al., 1989) , but occasionally no responses were observed (Abrams et al., 1990) . Co-administration of lymphokine-activated killer (LAK) cells Fisher et al., 1988; Foon et al., 1992; Palmer et al., 1992) al., 1987; Feruglio et al., 1992) , IFN-,B and IFN-y (Ernstoff et al., 1992) , have been studied for anti-tumour effects in RCC patients. Clinical data of IFN-# treatment combined with IL-2 suggest a better response rate than obtained with IFN-f or IL-2 therapy alone (Krigel et al., 1990) . These clinical data show that RCCs are responsive to immunotherapy, but that the anti-tumour effects of cytokines are limited by the toxicity of the therapy used.
Directing effector cells towards the tumour by using bispecific antibodies is a method to increase the specificity of the effector cell population for the targeted tumour cells. MOv18 expressed on ovarian carcinoma and the CD3 complex on T cells, resulted in several cases of tumour regression (Bolhuis et al., 1992; Canevari et al., 1995) . The G250 antigen is an attractive target for antibodymediated therapy, because of its nearly exclusive expression in renal carcinoma cells. Studies with the G250 MAb and the murine bispecific G250/OKT-3 (anti-CD3) MAb have shown preferential localisation of these antibodies to the tumour (Oosterwijk et al., 1993; van Dijk et al., 1991) and antitumour effects in RCC-xenografted nude mice (van Dijk et al., 1994) . The G250/anti-CD3 MAb was chimerised to decrease immunogenicity of the bispecific antibody in patients, because studies in patients with murine anti-tumour antibodies and bispecific antibodies are limited by the development of HAMA responses. These limitations may be greatly reduced by using chimeric antibodies for therapy (LoBuglio et al., 1989; Meredith et al., 1991) . A chimeric bispecific G250/anti-CD3 MAb provides the possibility of performing patient studies, in which multiple doses of the bispecific antibody can be administered over a long treatment period hopefully resulting in more extensive tumour regression.
We generated a cell line that produces chimeric bispecific G250/anti-CD3 MAb stably by supertransfection of a cell line producing chimeric anti-CD3 MAb with a single expression vector encoding both chimeric heavy and light chains of the G250 MAb. expression of the G250 antigen were shown to be lysed equally as well as tumour cells with a high G250 antigen expression. The chromatogram of the HPLC analysis of the antibody pool produced by clone T3 no. 36.4 revealed only two sharp and symmetrical peaks. One peak (1) corresponded to the chromatogram of G250 MAb and the other peak (2) represented the bispecific antibody fraction. The absence of a third peak representing parental anti-CD3 MAb was not the result of the loss of either the anti-CD3 MAb heavy or light chain, since RT-PCR analysis showed the presence of mRNA for all four antibody chains. The chromatographic separation method has been used previously to purify bispecific OVTL3/OKT-3 MAb ( van Ravenswaay Claasen et al., 1993) , murine bispecific OC/TR (Warnaar et al., 1994) , chimeric bispecific OC/TR (Coney et al., 1996) and murine bispecific G250/OKT-3 MAb (van Dijk et al., 1989) , and was shown to separate all combinations of heavy and light chains into distinguishable peaks. Therefore, we expect peak 2 of the chimeric G250/anti-CD3 MAb separation to contain IgG molecules composed of the parental heavy and light chains. We have no data to exclude mismatches in peak 2. However, De Lau et al. (1991) have shown that the production of two types of heavy and light chains by a quadroma does not necessarily lead to random association of these chains. Depending on the combination of parental antibodies, preferential association of heavy and light chains may occur, resulting in the absence of some heavy and light chain combinations. In addition, the profiles of the chromatograms of different clones producing the same bispecific OC/TR MAb have been shown to differ greatly, as a result of different rates of synthesis of the antibody chains (Warnaar et al., 1994) . In both the murine OC/TRproducing hybridoma and the chimeric OC/TR-producing hybridoma, clones were found that produced only one parental antibody and the bispecific MAb. The chromatogram of clone T3 no. 36.4 therefore represents one of the variants of the chromatograms that were observed among different clones producing other bispecific MAbs.
For any RCC patient to be treated with chimeric bispecific 743 G250/anti-CD3 MAb, the effector cell population to be activated will be a T cell of variable phenotype residing in the PBLs. IL-2-activated PBLs can be activated in vitro by chimeric bispecific G250/anti-CD3 MAb to lyse G250 antigen-expressing RCC cells. The activated PBL cytotoxicity may vary between donors and may vary according to the activation protocol (van Ravenswaay Claasen et al., 1993) . The in vitro cytotoxicity data suggest that treatment of RCC patients with chimeric bispecific G250/anti-CD3 MAb requires preactivation of the patients PBLs. Activated PBLs can be administered to the patient in combination with chimeric bispecific G250/anti-CD3 MAb, or altematively IL-2 can be given as in current IL-2-based regimens and bispecific G250/anti-CD3 MAb can be co-administered to enhance the effectiveness of IL-2-based therapy.
The murine versions of G250 and anti-CD3 MAb were immunogenic in patients, which was not the case for the chimeric versions (Dr E Oosterwijk, personal communication, Coney et al., 1996; Oosterwijk et al., 1993; Canevari et al., 1995) . Since the components of the chimeric bispecific G250/ anti-CD3 MAb did not induce an immune response, it is reasonable to expect that the chimeric bispecific MAb will also be non-immunogenic. Although humanisation of antibodies through CDR grafting is generally assumed to reduce immunogenicity further compared with chimeric antibodies, there is no solid patient data to support this notion. Humanised and chimeric antibodies have reduced immunogenicity compared with murine antibodies, however no direct comparison between humanised and chimeric MAbs has been performed. The fact that chimerisation of the G250 and anti-CD3 MAbs apparently abrogates the patients' immune response to the infused antibody, makes humanisation of the antibodies unnecessary. It is likely that any residual immunogenicity of chimeric or humanised antibodies will be idiotype dependent.
In conclusion, the chimeric bispecific G250/anti-CD3 MAb may represent a useful tool for enhancing the results obtained in RCC treatment using IL- 
